Defying malaria: Fathoming severe Plasmodium vivax disease

Q. Bassat,P. Alonso

DOI: https://doi.org/10.1038/nm0111-48

Nature Network Boston

Abstract:

What problem does this paper attempt to address?

Recent Advances and Prospects for Lipid-Based Nanoparticles As Drug Carriers in the Treatment of Human Retinal Diseases

Shaoxue Zeng,Yingying Chen,Fanfan Zhou,Ting Zhang,Xiaohui Fan,Wojciech Chrzanowski,Mark C. Gillies,Ling Zhu

DOI: https://doi.org/10.1016/j.addr.2023.114965

IF: 16.1

2023-01-01

Advanced Drug Delivery Reviews

Abstract:The delivery of cures for retinal diseases remains problematic. There are four main challenges: passing through multiple barriers of the eye, the delivery to particular retinal cell types, the capability to carry different forms of therapeutic cargo and long-term therapeutic efficacy. Lipid-based nanoparticles (LBNPs) are potent to overcome these challenges due to their unique merits: amphiphilic nanoarchitectures to pass biological barriers, vary modifications with specific affinity to target cell types, flexible capacity for large and mixed types of cargos and slow-release formulations for long-term treatment. We have reviewed the latest research on the applications of LBNPs for treating retinal diseases and categorized them by different payloads. Furthermore, we identified technical barriers and discussed possible future development for LBNPs to expand the therapeutic potential in treating retinal diseases.
Preparation and Biological Property Evaluation of Novel Cationic Lipid-Based Liposomes for Efficient Gene Delivery

Zhao Yunchun,Zheng Haili,Wang Xiaorong,Zheng Xiaoling,Zheng Yongquan,Chen Yue,Fei Weidong,Zhu Jiahuan,Wang Wenxi,Zheng Caihong

DOI: https://doi.org/10.1208/s12249-020-01868-w

IF: 3.3

2021-01-01

AAPS PharmSciTech

Abstract:Novel cationic lipid-based liposomes prepared using an amphiphilic cationic lipid material, N,N-dimethyl-(N′,N′-di-stearoyl-1-ethyl)1,3-diaminopropane (DMSP), have been proposed to enhance the transfection of nucleic acids. Herein, we designed and investigated liposomes prepared using DMSP, soybean phosphatidylcholine, and cholesterol. This novel gene vector has high gene loading capabilities and excellent protection against nuclease degradation. An in vitro study showed that the liposomes had lower toxicity and superior cellular uptake and transfection efficiency compared with Lipofectamine 2000. An endosomal escape study revealed that the liposomes demonstrated high endosomal escape and released their genetic payload in the cytoplasm efficiently. Mechanistic studies indicated that the liposome/nucleic acid complexes entered cells through energy-dependent endocytosis that was mediated by fossa proteins. These results suggest that such cationic lipid-based liposome vectors have potential for clinical gene delivery.
Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation, characterization and efficacy in Parkinsons disease

KaiLi Hu,Yanbin Shi,WenMing Jiang,Jiaying Han,Shixian Huang,Xinguo Jiang

DOI: https://doi.org/10.1016/j.ijpharm.2011.05.062

IF: 6.51

2011-01-01

International Journal of Pharmaceutics

Abstract:A novel biodegradable brain drug delivery system, the lactoferrin (Lf) conjugated polyethylene glycol-polylactide-polyglycolide (PEG-PLGA) nanoparticle (Lf-NP) was constructed in this paper with its in vitro and in vivo delivery properties evaluated by a fluorescent probe coumarin-6. Lf was thiolated and conjugated to the distal maleimide function surrounding on the pegylated nanoparticle to form Lf-NP. TEM observation and ELISA analysis confirmed the existence of active Lf on the surface of Lf-NP. The results of qualitative and quantitative uptake studies of coumarin-6 incorporated Lf-NP showed a more pronounced accumulation of Lf-NP in bEnd.3 cells than that of unconjugated nanoparticle (NP). Further uptake inhibition study indicated that the increased uptake of Lf-NP was via an additional clathrin mediated endocytosis processes. Following intravenous administration, a near 3 fold of coumarin-6 was found in the mice brain carried by Lf-NP compared to that carried by NP. Intravenous injection of urocortin loaded Lf-NP effectively attenuated the striatum lesion caused by 6-hydroxydopamine in rats as indicated by the behavioral test, the immunohistochemistry test and striatal transmitter content detection results. The cell viability test and CD68 immunohistochemistry demonstrated the acceptable toxicity of the system. All these results demonstrated that Lf-NP was a promising brain drug delivery system with reasonable toxicity.
Novel liposomal formulations for protection and delivery of levodopa: Structure-properties correlation

Elena Allegritti,Sara Battista,Maria Anna Maggi,Claudia Marconi,Luciano Galantini,Luisa Giansanti

DOI: https://doi.org/10.1016/j.ijpharm.2023.123230

2023-08-25

Abstract:Liposomes are promising drug carriers for a wide range of central nervous system disorders, such as Parkinson's disease (PD), since they can protect active substances from degradation and could be administered intranasally, ensuring a direct access to the brain. Levodopa (LD), the drug commonly used to treat PD, spontaneously oxidizes in aqueous solutions and thus needs to be stabilized. Our investigation focuses on the preparation and the physico-chemical characterization of mixed liposomes to vehiculate LD and two natural substances (L-ascorbic acid and quercetin) that can prevent its oxidation and contribute to the treatment of Parkinson's disease. These co-loaded vesicles were prepared using a saturated phospholipid and structurally related cationic or analogue N-oxide surfactants and showed different properties, based on their composition. In particular, ex-vivo permeability tests using porcine nasal mucosa were performed, denoting that subtle variations of the lipids structure can significantly affect the delivery of LD to the target site.
Nanoemulsion-Templated Shell-Crosslinked Nanocapsules As Drug Delivery Systems

Wei He,Yi Lu,Jianping Qi,Lingyun Chen,Fuqiang Hu,Wei Wu

DOI: https://doi.org/10.1016/j.ijpharm.2013.01.072

IF: 6.51

2013-01-01

International Journal of Pharmaceutics

Abstract:A novel biocompatible shell-crosslinked nanocapsule system was developed based on nanoemulsion templates stabilized by a class of food proteins. The nanoemulsion templates were prepared using a combination of mechanical mixing and high-pressure homogenization, while the nanocapsule shell formed simultaneously through calcium ions-induced crosslinking of the food proteins. These core–shell structured nanocapsules with a particle size of about 200nm showed high drug-loading capacity and well improved stability in comparison with their nanoemulsion counterpart. The nanocapsule suspension can be freeze-fried directly; and the solidified nanocapsules can be well reconstituted in water, retaining their original particle size. It is concluded that the nanoemulsion-templated core–shell structured nanocapsules can be used as novel drug delivery systems with high loading capacity for poorly water-soluble drugs as well as well improved long-term and storage stability. Furthermore, the presence of surface food proteins introduces carboxyl and amine moieties, which enables the nanocapsules to anchor ligands, suggesting its potential application in targeting drug delivery, bioimaging and therapeutics.
Assessing availability, phytotoxicity and bioaccumulation of lead to ryegrass and millet based on 0.1 mol/L ca(NO3)2 extraction.

Si Ji-tao,Tian Bao-guo,Wang Hong-tao,N. Basta,J. Schroder,M. Casillas

DOI: https://doi.org/10.1016/S1001-0742(06)60021-1

2006-09-01

Journal of Environmental Science

Abstract:
Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting.

Fulan Xie,Nian Yao,Yao Qin,Qianyu Zhang,Huali Chen,Mingqing Yuan,Jie Tang,Xiankun Li,Wei Fan,Qiang Zhang,Yong Wu,Li Hai,Qin He

DOI: https://doi.org/10.2147/IJN.S23771

IF: 7.033

2012-01-01

International Journal of Nanomedicine

Abstract:BACKGROUND:An intimidating challenge to transporting drugs into the brain parenchyma is the presence of the blood-brain barrier (BBB). Glucose is an essential nutritional substance for brain function sustenance, which cannot be synthesized by the brain. Its transport primarily depends on the glucose transporters on the brain capillary endothelial cells. In this paper, the brain-targeted properties of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers were compared and evaluated to establish an optimized drug-delivery system. METHODS:Coumarin 6-loaded liposomes (GLU200-LIP, GLU400-LIP, GLU1000-LIP, and GLU2000-LIP) composed of phospholipids and glucose-derived cholesterols were prepared by thin-film dispersion-ultrasound method. The BBB model in vitro was developed to evaluate the transendothelial ability of the different liposomes crossing the BBB. The biodistribution of liposomes in the mice brains was identified by in vivo and ex vivo nearinfrared fluorescence imaging and confocal laser scanning microscopy and further analyzed quantitatively by high-performance liquid chromatography. RESULTS:Glucose-derived cholesterols were synthesized and identified, and coumarin 6-loaded liposomes were prepared successfully. The particle sizes of the four types of glucose-modified liposomes were around or smaller than 100 nm with a polydispersity index less than 0.300. GLU400-LIP, GLU1000-LIP, and GLU2000-LIP achieved higher cumulative cleared volumes on BBB model in vitro after 6 hours compared with GLU200-LIP (P < 0.05) and were significantly higher than that of the conventional liposome (P < 0.001). The qualitative and quantitative biodistribution results in the mice showed that the accumulation of GLU1000-LIP in the brain was the highest among all the groups (P < 0.01 versus LIP). CONCLUSION:The data indicated that GLU400-LIP, GLU1000-LIP, and GLU2000-LIP all possess the potential of brain targeting, among which GLU1000-LIP, as a promising drug-delivery system, exhibited the strongest brain delivery capacity.
A Novel Lactoferrin-Modified Β-Cyclodextrin Nanocarrier for Brain-Targeting Drug Delivery.

Yajing Ye,Yi Sun,Hongli Zhao,Minbo Lan,Feng Gao,Chao Song,Kaiyan Lou,Hao Li,Wei Wang

DOI: https://doi.org/10.1016/j.ijpharm.2013.10.005

IF: 6.51

2013-01-01

International Journal of Pharmaceutics

Abstract:The blood-brain barrier (BBB) restricts the transfer and delivery of most drug substances to brain. In this study, a novel nano-drug delivery system for brain-targeting was developed and investigated in vitro and in vivo. Lactoferrin (Lf) was selected as a brain-targeting ligand and conjugated to beta-cyclodextrin (beta-CD) via the heterobifunctional polyethyleneglycol (PEG) linker NHS-PEG-MAL, yielding Lf conjugated beta-cyclodextrin (Lf-CD). UV-vis, FTIR, NMR and transmission electron microscopy (TEM) techniques clearly demonstrated the successful synthesis of Lf-CD nanoparticles with the average diameter of 92.9 +/- 16.5 nm. Using near-infrared fluorescent dye IR-775 chloride (IR) as a model compound of poorly water-soluble drugs, IR-loaded Lf-CD nanoparticles (Lf-CD/IR) were successfully prepared with a high entrapment efficiency of 98.1 +/- 4.8%. Biodistribution and pharmacokinetics of Lf-CD/IR were evaluated in KM mice after intravenous administration. The results of tissue distribution studies revealed that Lf-CD/IR treatment showed greatly improved BBB transport efficiency. In addition, AUC(0-2) h of IR in brain after Lf-CD/IR treatment was seven fold higher compared with that of IR treatment without Lf-CD nanocarriers, demonstrating that the introduction of Lf-CD drug-delivery system positively resulted in a higher AUC located in brain tissue. These results provide evidence that Lf-CD nanoparticles could be exploited as a potential brain-targeting drug delivery system for hydrophobic drugs and diagnostic reagents which normally fail to pass through the BBB. (C) 2013 Elsevier B.V. All rights reserved.
Co-loading of Levodopa and Curcumin Using Brain-targeted Protocells for Improving the Efficacy of Parkinson's Disease

Wenkai Zhou,Chang Liu,Feifei Yu,Xia Niu,Xiaomei Wang,Guiling Li,Xinru Li

DOI: https://doi.org/10.21203/rs.3.rs-131164/v1

2021-01-01

Abstract:Abstract Parkinson's disease (PD), one of the most common movement and neurodegenerative disorders, is challenging to treat. Levodopa is a common clinical drug for controlling the symptoms of PD, but it only replenishes the missing dopamine, can’t protect dopaminergic neurons. While curcumin as a neuroprotective agent has been reported for treatment of PD. Herein, we present a novel organic-inorganic composite nanoparticle with brain targeting (lf-protocells) for co-delivery of levodopa and curcumin, and demonstrate its attractive use as a biocompatible platform for PD treatment. The nanoparticle system is comprised of a lactoferrin (lf) modified lipid bilayer (LB) containing curcumin as its outer membrane and mesoporous silica nanoparticles (MSNs) containing levodopa as its supporting inner core. Our studies illustrate that the lf-protocells have a spherical morphology, and can be used to co-load levodopa and curcumin efficiently; the combination of curcumin and levodopa alleviates the apoptosis of PD cells, decreases the expression of a-synuclein and increase the expression of tyrosine hydroxylase in SH-SY5Y cells as compared to single drug; the binary-drug loaded lf-protocells ameliorate oxidative stress and mitochondrial dysfunction as compared to combination of free drugs; lf-protocells improve significantly the distribution in brain compared with unmodified protocells; binary-drug loaded lf-protocells have better performance of motor function in mouse than unmodified protocells and combination of free drugs. In conclusion, binary-drug loaded lf-protocells show better therapeutic efficacy in both cell model and mouse model of PD than combination of free drugs and lower toxicity than bare MSNs. These results suggest that lf-protocells can be used as a promising drug delivery platform for targeted therapy against PD and other diseases of the central nervous system.
Self-Assembled Polymersomes Conjugated with Lactoferrin as Novel Drug Carrier for Brain Delivery

Yuan Yu,Zhiqing Pang,Wei Lu,Qi Yin,Huile Gao,Xinguo Jiang

DOI: https://doi.org/10.1007/s11095-011-0513-7

IF: 4.58

2011-01-01

Pharmaceutical Research

Abstract:BSTRACT Purpose To develop a novel brain drug delivery system based on self-assembled poly(ethyleneglycol)-poly (D,L-lactic-co-glycolic acid) (PEG-PLGA) polymersomes conjugated with lactoferrin (Lf-POS). The brain delivery properties of Lf-POS were investigated and optimized. Method Three formulations of Lf-POS, with different densities of lactoferrin on the surface of polymersomes, were prepared and characterized. The brain delivery properties in mice were investigated using 6-coumarin as a fluorescent probe loaded in Lf-POS (6-coumarin-Lf-POS). A neuroprotective peptide, S14G-humanin, was incorporated into Lf-POS (SHN-Lf-POS); a protective effect on the hippocampuses of rats treated by Amyloid-β 25-35 was investigated by immunohistochemical analysis. Results The results of brain delivery in mice demonstrated that the optimized number of lactoferrin conjugated per polymersome was 101. This obtains the greatest blood–brain barrier (BBB) permeability surface area( PS ) product and percentage of injected dose per gram brain (%ID/g brain). Immunohistochemistry revealed the SHN-Lf-POS had a protective effect on neurons of rats by attenuating the expression of Bax and caspase-3 positive cells. Meanwhile, the activity of choline acetyltransferase (ChAT) had been increased compared with negative controls. Conclusion These results suggest that lactoferrin functionalized self-assembled PEG-PLGA polymersomes could be a promising brain-targeting peptide drug delivery system via intravenous administration.
Lactoferrin-conjugated PEG–PLA Nanoparticles with Improved Brain Delivery: in Vitro and in Vivo Evaluations

Kaili Hu,Jingwei Li,Yehong Shen,Wei Lu,Xiaoling Gao,Qizhi Zhang,Xinguo Jiang

DOI: https://doi.org/10.1016/j.jconrel.2008.10.016

IF: 11.467

2009-01-01

Journal of Controlled Release

Abstract:The lactoferrin (Lf) conjugated poly (ethyleneglycol)-poly (lactide) nanoparticle (Lf-NP) was constructed in this paper as a novel biodegradable brain drug delivery system with evaluation of its in vitro and in vivo delivery properties. Lf was thiolated and conjugated to the distal maleimide functions surrounding on the pegylated nanoparticles to form the Lf-NP. The existence of Lf on the surface of Lf-NP was verified by TEM observation and XPS analysis. The Lf ELISA results confirmed the biorecognitive activity of Lf after the coupling procedure and suggested the average number of Lf conjugated on each nanoparticle was around 55. To evaluate the brain delivery properties of the Lf-NP, a fluorescent probe, coumarin-6 was incorporated into it. The uptake of Lf-NP by bEnd.3 cells was shown significantly higher than that of unconjugated nanoparticle (NP). Following an intravenous administration, a near 3 folds of coumarin-6 were found in the mice brain carried by Lf-NP compared to that carried by NP. Cell viability experiment results confirmed good safety of the biodegradable Lf-NP. The significant in vitro and in vivo results suggest that Lf-NP is a promising brain drug delivery system with low toxicity.
Brain-targeted Drug Delivery by in Vivo Functionalized Liposome with Stable D-peptide Ligand.

Yang,Yuxiu Chu,Cheng Li,Lianfeng Fan,Huiping Lu,Changyou Zhan,Zui Zhang

DOI: https://doi.org/10.1016/j.jconrel.2024.07.014

IF: 11.467

2024-01-01

Journal of Controlled Release

Abstract:Brain-targeted drug delivery poses a great challenge due to the blood-brain barrier (BBB). In a previous study, we have developed a peptide-modified stealth liposome (SP-sLip) to enhance BBB penetration via the adsorption of apolipoproteins in plasma. SP is an 11-amino acid peptide derived from 25 to 35 of the Amyloid beta peptide (A beta(1-42)), which is a nature ligand of apolipoproteins. Although freshly prepared SP-sLip exhibited efficient brain targeting performance, it occured self-aggregation and instability in storage. In this study, we developed a D-peptide ligand according to the reverse sequence of SP with D-amino acids, known as (SP)-S-D, to improve the stability in storage. Notably, (SP)-S-D exhibited a reduced tendency for self-aggregation and improved stability in comparison to the SP peptide. Furthermore, compared to SP-sLip, (SP)-S-D-modified sLip ((SP)-S-D-sLip) demonstrated enhanced stability (>2 weeks), prolonged blood circulation (AUC increased 44.4%), reduced liver and spleen accumulation (reduced by 2.23 times and 1.86 times) with comparable brain-targeting efficiency. Similar to SP-sLip, (SP)-S-D-sLip selectively adsorbed apolipoprotein A1, E, and J in the blood to form functionalized protein corona, thus crossing BBB via apolipoprotein receptor-mediated transcytosis. These findings underscored the importance of ligand stability in the in vitro and in vivo performance of brain-targeted liposomes, therefore paving the way for the design and optimization of efficient and stable nanocarriers.
Solid lipid nanoparticles as a vehicle for brain-targeted drug delivery: two new strategies of functionalization with apolipoprotein E

Ana Rute Neves,Joana Fontes Queiroz,Babette Weksler,Ignacio A Romero,Pierre-Olivier Couraud,Salette Reis

DOI: https://doi.org/10.1088/0957-4484/26/49/495103

IF: 3.5

2015-11-17

Nanotechnology

Abstract:Nanotechnology can be an important tool to improve the permeability of some drugs for the blood-brain barrier. In this work we created a new system to enter the brain by functionalizing solid lipid nanoparticles with apolipoprotein E, aiming to enhance their binding to low-density lipoprotein receptors on the blood-brain barrier endothelial cells. Solid lipid nanoparticles were successfully functionalized with apolipoprotein E using two distinct strategies that took advantage of the strong interaction between biotin and avidin. Transmission electron microscopy images revealed spherical nanoparticles, and dynamic light scattering gave a Z-average under 200 nm, a polydispersity index below 0.2, and a zeta potential between -10 mV and -15 mV. The functionalization of solid lipid nanoparticles with apolipoprotein E was demonstrated by infrared spectroscopy and fluorimetric assays. In vitro cytotoxic effects were evaluated by MTT and LDH assays in the human cerebral microvascular endothelial cells (hCMEC/D3) cell line, a human blood-brain barrier model, and revealed no toxicity up to 1.5 mg ml(-1) over 4 h of incubation. The brain permeability was evaluated in transwell devices with hCMEC/D3 monolayers, and a 1.5-fold increment in barrier transit was verified for functionalized nanoparticles when compared with non-functionalized ones. The results suggested that these novel apolipoprotein E-functionalized nanoparticles resulted in dynamic stable systems capable of being used for an improved and specialized brain delivery of drugs through the blood-brain barrier.

materials science, multidisciplinary,physics, applied,nanoscience & nanotechnology
Multiple targeted doxorubicin-lonidamine liposomes modified with p-hydroxybenzoic acid and triphenylphosphonium to synergistically treat glioma

Jiaqi Lu,Ru Li,Binsong Mu,Yao Peng,Yi Zhao,Yuesen Shi,Li Guo,Li Hai,Yong Wu

DOI: https://doi.org/10.1016/j.ejmech.2021.114093

IF: 7.088

2022-02-01

European Journal of Medicinal Chemistry

Abstract:A type of pH-sensitive multi-targeted brain tumor site-specific liposomes (Lip-CTPP) co-modified with p-hydroxybenzoic acid (p-HA) and triphenylphosphonium (TPP) were designed and prepared to co-load doxorubicin (DOX) and lonidamine (LND). Lip-CTPP are promising potential carriers to exert the anti-glioma effect of DOX and LND collaboratively given the following features: 1) Lip-CTPP have a good pharmacokinetic behavior; 2) Lip-CTPP can cross the blood-brain barrier (BBB) and recognize tumor cells through the affinity of p-HA and dopamine/sigma receptors; 3) Lip-CTPP are highly positive charged once the acid-sensitive amide bonds are cleaved in endo/lysosomes to expose TPP and protonate amine groups; 4) the positive charged Lip-CTPP escape from endo/lysosomes and accumulate in mitochondria through electrostatic adsorption; 5) DOX and LND are released and synergistically increase anti-tumor efficacy. Our in vitro and in vivo results confirmed that Lip-CTPP could greatly elevate the inhibition rate of tumor cell proliferation, migration and invasion, promote apoptosis and necrosis, and interfere with mitochondrial function. In addition, Lip-CTPP could significantly prolong the survival time of glioma bearing mice, narrow the tumor region and inhibit the infiltration and metastasis capability of glioma cells. Collectively, Lip-CTPP are promising nano formulations to enhance the synergistic effect of DOX and LND in glioma treatment.

chemistry, medicinal
Development of L-carnosine functionalized iron oxide nanoparticles loaded with dexamethasone for simultaneous therapeutic potential of blood brain barrier crossing and ischemic stroke treatment

Xianfeng Lu,Yaohui Zhang,Lixiang Wang,Guichen Li,Jianyuan Gao,Ying Wang

DOI: https://doi.org/10.1080/10717544.2021.1883158

IF: 6.819

2021-01-01

Drug Delivery

Abstract:The development of suitable drug delivery carriers is significant in biomedical applications to improve the therapeutic efficiency. Recent progress in nanotechnological fields, paved the way for the formulation of variety of drug carriers. The brain disorders such as ischemic stroke, brain cancer, and CNS disorders were poorly treated due to the presence of blood brain barrier that hinders the passage of drugs to the brain. Hence, the formulated drugs should have the ability to cross the blood-brain barrier (BBB) for ischemic stroke treatment. In the present work, we have synthesized PLGA functionalized magnetic Fe3O4 nanoparticle (MNP) with L-carnosine peptide (LMNP) composite loaded with dexamethasone (dm@LMNP) and demonstrated as efficient drug delivery platform for simultaneous BBB crossing and treatment of ischemic stroke. The surface morphology, particles size and zeta potential of the prepared material was studied from SEM, PSD, PDI and TEM analyses. The drug loading of dexamethasone in LMNP (dm@LMNP) vesicles was found to be 95.6 ± 0.2%. The in vitro drug release kinetics displayed that prepared composited LMNP material provides controlled and sustainable releasing efficiency at pH 7.4 and 5.8 when compared to the PLGA NPs and free dexamethasone drug molecules. The cytotoxicity and the biocompatibility test results were found to be satisfactory. The L-carnosine loaded nano-formulation has been greatly leads to effective BBB crossing to access the brain tissues. These results showed that the Fe3O4 nanoparticles/PLGA polymer can be used as an effective drug carrier for the treatment of stroke and simultaneous blood brain barrier crossing.

pharmacology & pharmacy
Development of a concentration‐controlled sequential nanoprecipitation for making lipid nanoparticles with high drug loading

Letao Xu,Xing Wang,Guangze Yang,Zihan Zhao,Yilun Weng,Yang Li,Yun Liu,Chun‐Xia Zhao

DOI: https://doi.org/10.1002/agt2.369

2023-06-18

Aggregate

Abstract:A concentration‐controlled sequential nanoprecipitation platform technology has been developed for fabricating lipid‐based nanoparticles with tunable drug loading up to 70% wt. This method achieves the precise control over lipid nanoparticle formation by tuning the precipitation sequence of drug and lipids, and it is applicable for encapsulating a broad range of drugs with various hydrophobicity. Lipid‐based nanostructures have garnered considerable interests over the last two decades, and have achieved tremendous clinical success including the first clinical approval of a liposome (Doxil) for cancer therapy in 1995 and the recent COVID‐19 mRNA lipid nanoparticle vaccines. Compared to liposomes which have a lipid bilayer surrounding an aqueous core, lipid nanoparticles with a particle structure have several attractive advantages for encapsulating poorly water‐soluble drugs such as better stability due to the particle structure, high drug encapsulation efficiency because of a pre‐ or co‐drug‐loading strategy. While many studies have reported the synthesis of lipid nanoparticles for hydrophobic drug encapsulation, the precise control of drug loading and encapsulation efficiency remains a significant challenge. This work reports a new concentration‐controlled nanoprecipitation platform technology for fabricating lipid nanoparticles with tunable drug loading up to 70 wt%. This method is applicable for encapsulating a wide range of drugs from very hydrophobic to slightly hydrophilic. Using this facile method, nanoparticles with tunable drug loading exhibited excellent properties such as small particle size, narrow size distribution, good particle stability, showing great promise for future drug delivery applications.

chemistry, multidisciplinary, physical,materials science
Targeted Liposomal Co-Delivery Dopamine with 3-n-Butylphthalide for Effective Against Parkinson's Disease in Mice Model

Yi Liang,Liping Feng,Yue Zheng,Yunzhen Gao,Rongying Shi,Zhirong Zhang,Xue Ying,Yingchun Zeng

DOI: https://doi.org/10.2147/IJN.S483595

2024-11-30

Abstract:Introduction: Parkinson's disease (PD) is a multifactor-induced neurodegenerative disease with high incidence in the elderly population. We found for the first time that the combination of dopamine (DA) and 3-n-butylphthalide (NBP) has great potential for the synergistic treatment of PD. To further improve the therapeutic performance of the drugs, a brain-targeting liposomal co-delivery system encapsulating NBP and DA ((NBP+DA)-Lips-RVG29) was designed using a rabies virus polypeptide with 29 amino acids (RVG29) as the targeting ligand. Methods: The synergistic neuroprotective effects of NBP and DA were assessed in 6-OHDA-induced PC12 cells. Then, (NBP+DA)-Lips-RVG29 loading with NBP and DA at an optimal ratio was prepared using the thin-film hydration and sonication method. The physicochemical and biological characterization of (NBP+DA)-Lips-RVG29 were systemically investigated, and the therapeutic efficiency and underlying mechanisms of (NBP+DA)-Lips-RVG29 were also explored in vitro and in vivo. Finally, the safety of (NBP+DA)-Lips-RVG29 was evaluated. Results: The synergistic effects of NBP and DA peaked at 1:1 (NBP/DA, mol/mol). The functionalized liposomes showed significantly higher uptake efficiency and blood-brain barrier (BBB) penetration efficiency in vitro. After systemic administration, (NBP+DA)-Lips-RVG29 prolonged the blood circulation of drugs, enhanced BBB penetration and increased drug accumulation in the striatum, substantia nigra and hippocampus. Moreover, (NBP+DA)-Lips-RVG29 showed excellent neuroprotective effects in a cellular PD model of PC12 cells and improved therapeutic efficacy in a PD mouse model. Furthermore, the safety evaluation of (NBP+DA)-Lips-RVG29 revealed no systemic toxicity. Conclusion: NBP and DA exhibited the synergistic anti-PD effects. The RVG29-modified liposomes encapsulating NBP and DA contributed to the accumulation of drugs in the brain lesions area of PD and further improved treatment efficacy. Therefore, (NBP+DA)-Lips-RVG29 represents a promising strategy for the treatment of PD and other neurodegenerative diseases.
Dopamine-loaded chitosan-coated solid lipid nanoparticles as a promise nanocarriers to the CNS

Elena Ortega Martínez,Ma Encarnación Morales Hernández,Julia Castillo-González,Elena González-Rey,Ma Adolfina Ruiz Martínez

DOI: https://doi.org/10.1016/j.neuropharm.2024.109871

IF: 5.273

2024-02-26

Neuropharmacology

Abstract:Dopamine is unable to access the central nervous system through the bloodstream. Only its precursor can do so, and with an effectiveness below 100% of the dose administered, as it is metabolized before crossing the blood-brain barrier. In this study, we describe a new solid lipid nanocarrier system designed and developed for dopamine. The nanoparticles were prepared by the melt-emulsification method and then coated with chitosan. The nanocarriers developed had a droplet size of about 250 nm, a polydispersity index of 0.2, a positive surface charge (+30 mV), and a percentage encapsulation efficiency of 36.3 ± 5.4. Transmission and scanning electron microscopy verified uniformity of particle size with spherical morphology. Various types of tests were performed to confirm that the nanoparticles designed are suitable for carrying dopamine through the blood-brain barrier. In vitro tests demonstrated the ability of these nanocarriers to pass through endothelial cell monolayers without affecting their integrity. This study shows that the formulation of dopamine in chitosan-coated solid lipid nanoparticles is a potentially viable formulation strategy to achieve the bioavailability of the drug for the treatment of Parkinson's disease in the central nervous system.

pharmacology & pharmacy,neurosciences
Identification of volatile allelochemicals fromAmaranthus palmeri S. Wats

W. Connick,J. M. Bradow,M. Legendre,S. Vail,R. M. Menges

DOI: https://doi.org/10.1007/BF01880093

1987-03-01

Journal of Chemical Ecology

Abstract:
Preparation and Drug Release Study of Novel Nanopharmaceuticals with Polysorbate 80 Surface Adsorption

Xiaojun Tao,Yu Li,Qian Hu,Li Zhu,Zixuan Huang,Jiajin Yi,Xiaoping Yang,Jianzhuo Hu,Xing Feng

DOI: https://doi.org/10.1155/2018/4718045

IF: 3.791

2018-01-01

Journal of Nanomaterials

Abstract:Most free drugs that cross the blood–brain barrier are characterized by high liposolubility, but they often have limited clinical applications because of poor dissolution and poor bioavailability. In this study, we prepared donepezil drug-loaded nanoparticles (DZP) with cholesterol-modified pullulan (CHP) as the nanocarrier (DZP-CHP) and surface modified the drug-loaded nanoparticles to improve the water solubility of donepezil while enhancing its targeting and sustained release. We determined the drug loading and encapsulation efficiency of DZP-CHP nanoparticles at different feed ratios. The mean ± SD drug loading and entrapment efficiency were high: 13.52 ± 2.03 and 86.54 ± 1.31. On dynamic light-scattering measurement, mean ± SD particle size was 260.7 ± 1.76 nm, polydispersity index 0.123 ± 0.004, and zeta potential −5.75 ± 0.64 mV. DZP-CHP nanoparticles prepared with the optimal feed ratio (DZP : CHP = 1 : 5) were coated with polysorbate 80, and the adsorption process was determined by isothermal titration calorimetry. We found good affinity between polysorbate 80 and DZP-CHP, with mean ± SD coverage 2.7 ± 0.372. The mean ± SD drug loading and entrapment efficiency of polysorbate 80-emulsified DZP-CHP nanoparticles were 8.25 ± 1.80 and 91.28 ± 4.57, respectively, and the proportion of drug released by 72 h was 42.71%. Compared to DZP-CHP alone, PS-DZP-CHP can enhance the release of donepezil.

materials science, multidisciplinary,nanoscience & nanotechnology

Defying malaria: Fathoming severe Plasmodium vivax disease

Recent Advances and Prospects for Lipid-Based Nanoparticles As Drug Carriers in the Treatment of Human Retinal Diseases

Preparation and Biological Property Evaluation of Novel Cationic Lipid-Based Liposomes for Efficient Gene Delivery

Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation, characterization and efficacy in Parkinsons disease

Novel liposomal formulations for protection and delivery of levodopa: Structure-properties correlation

Nanoemulsion-Templated Shell-Crosslinked Nanocapsules As Drug Delivery Systems

Assessing availability, phytotoxicity and bioaccumulation of lead to ryegrass and millet based on 0.1 mol/L ca(NO3)2 extraction.

Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting.

A Novel Lactoferrin-Modified Β-Cyclodextrin Nanocarrier for Brain-Targeting Drug Delivery.

Co-loading of Levodopa and Curcumin Using Brain-targeted Protocells for Improving the Efficacy of Parkinson's Disease

Self-Assembled Polymersomes Conjugated with Lactoferrin as Novel Drug Carrier for Brain Delivery

Lactoferrin-conjugated PEG–PLA Nanoparticles with Improved Brain Delivery: in Vitro and in Vivo Evaluations

Brain-targeted Drug Delivery by in Vivo Functionalized Liposome with Stable D-peptide Ligand.

Solid lipid nanoparticles as a vehicle for brain-targeted drug delivery: two new strategies of functionalization with apolipoprotein E

Multiple targeted doxorubicin-lonidamine liposomes modified with p-hydroxybenzoic acid and triphenylphosphonium to synergistically treat glioma

Development of L-carnosine functionalized iron oxide nanoparticles loaded with dexamethasone for simultaneous therapeutic potential of blood brain barrier crossing and ischemic stroke treatment

Development of a concentration‐controlled sequential nanoprecipitation for making lipid nanoparticles with high drug loading

Targeted Liposomal Co-Delivery Dopamine with 3-n-Butylphthalide for Effective Against Parkinson's Disease in Mice Model

Dopamine-loaded chitosan-coated solid lipid nanoparticles as a promise nanocarriers to the CNS

Identification of volatile allelochemicals fromAmaranthus palmeri S. Wats

Preparation and Drug Release Study of Novel Nanopharmaceuticals with Polysorbate 80 Surface Adsorption